Jung Baopu, Chairman of ChemExpress (left), and Han Taedong, CEO of Aptis (right), are taking a commemorative photo after signing a business agreement at the ChemExpress headquarters in Shanghai, China. Photo by Aptis
Aptis, a company specializing in the development of ADC (antibody-drug conjugate) therapeutics, announced on May 13 that it has signed a Toolbox Partnership Memorandum of Understanding (MOU) with ChemExpress, an ADC CDMO (contract development and manufacturing organization) based in Shanghai, China.
The Toolbox Partnership is an integrated platform that combines different technologies and solutions in an organic manner to provide services that customers can select and utilize according to their specific needs.
Aptis aims to improve the safety and efficacy of conventional ADCs through its proprietary site-specific antibody conjugation technology platform, AbClick®. ChemExpress is a CDMO specializing in the ADC field, offering a one-stop platform that covers everything from research and development to GMP (Good Manufacturing Practice) production.
Through this agreement, Aptis and ChemExpress plan to integrate their ADC research and development capabilities and share their global networks. This collaboration is expected to attract new customers, pioneer new markets, and provide innovative and efficient solutions to client companies.
In particular, the two companies plan to combine their core competencies not only in the AbClick platform but also across antibody conjugation technologies and the broader industrialization process, jointly promoting the development of next-generation ADCs.
Through these efforts, they aim to strengthen the competitiveness of the global ADC industry and create ongoing value for human health by delivering innovative therapeutics to patients more rapidly.
Han Taedong, CEO of Aptis, stated, "ChemExpress is one of the first companies to begin ADC research in China and has strengths in both technological capabilities and a pool of specialized talent. By combining the AbClick technology platform with ChemExpress's capabilities, the application of site-specific antibody conjugation technology will be further expanded, and we will be able to contribute to providing safer and more effective precision therapeutics to patients."
Jung Baopu, Chairman of ChemExpress, said, "We are very pleased to enter into a strategic agreement with Aptis, which possesses the third-generation antibody conjugation technology platform AbClick. Through this collaboration, we expect to maximize the strengths of both companies, accelerate the development of new ADC and bioconjugate drugs, and deliver benefits to global patients more quickly."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
